Ownership history in Qube Research & Technologies Ltd Β· 9 quarters on record
This page tracks every 13F SEC filing in which Qube Research & Technologies Ltd reported a position in SILVERBACK THERAPEUTICS INC (SPRY). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Qube Research & Technologies Ltd underperformed the S&P 500 by β15.9% annually on this SPRY position. Timing score: 12% (1/8 decisions correct). Average cost basis: $10.67. Maximum drawdown during holding period: β90.9%.
β Significantly underperformed the S&P 500 by 15.9% ann.
8 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
1 of 8 add/trim decisions correct
Best entry: $6.51 (2023 Q1) Β· Worst: $46.34 (2020 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
6 adds Β· 3 trims. Bought during 3 of 4 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.01% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size